Navigation Links
InterMune Announces Progress on Pirfenidone in IPF
Date:4/21/2008

c Society (ATS), entitled, "A Phase III, Double-Blind, Placebo-Controlled Clinical Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Japan" [Session C95], is now posted at http://www.thoracic.org.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects a total of approximately 200,000 people in the United States and Europe, with approximately 30,000 new cases developing in the United States alone, each year. There are no medicines approved by the U.S. Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMEA) for the treatment of IPF. IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years.

About Pirfenidone

Prior in vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Data presented from one Phase 3 study and four Phase 2 clinical trials in more than 400 patients suggest that pirfenidone may positively affect lung function and disease progression in patients with IPF. In these clinical studies, pirfenidone was generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. Pirfenidone has been granted orphan drug designation in the both the United States and Europe for the treatment of IPF.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and h
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
2. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3. InterMune Announces Start of Phase 1b Trial of ITMN-191
4. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
(Date:9/2/2014)... 2014 According to the new ... Analytical, Preparative), by Material (Metal, Glass, Plastic), by Application ... to 2018", published by MarketsandMarkets, the Chiral Chromatography Columns ... poised to grow at a CAGR of 5.2% from ... Browse 90 market data tables and 15 figures ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... present an overview of the company at the Morgan Stanley ... , Presentation date: Tuesday September 9, 2014 ... A live webcast and 30-day archive of this presentation will ... Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... 15 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), ... present a company overview at the 17th Annual NewsMakers in ... 11:00 a.m. ET at the Millennium Broadway Hotel & Conference ... of the presentation will be available on the "Investors & ...
... Md., Oct. 15 /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: ... in China and a producer, marketer and seller of ... that the Company will present at Citi,s Greater China ... the Grand Hyatt Macau.  Management is currently scheduled to ...
Cached Medicine Technology:
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 (HealthDay ... behind the rising rates of type 2 diabetes, according to ... national surveys spanning from 1976 through 2010 to determine how ... by factors such as changing distribution of race, age and ... prevalence of diabetes in men rose from about 5 percent ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
(Date:9/2/2014)... and marijuana may lead to different types of harmful ... analyzed 2007 to 2011 data gathered from more than ... used alcohol or marijuana at least once. The ... unsafe driving, damage to relationships with friends and romantic ... of alcohol, especially among females. On the ...
(Date:9/2/2014)... in locations with less intensive (and expensive) practice patterns ... that spare patients unnecessary and excessive medical care, according ... . , "Growing concern about the costs and harms ... ability to avoid the provision of unnecessary care," said ... and The Dartmouth Institute for Health Policy & ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Residency training predicts physicians' ability to practice conservatively 2
... WASHINGTON, Sept. 18 Americans believe that,providing medical care ... top of our nation,s priorities, in line with resolving ... a new nationwide survey. What,s,more, three-quarters of the public ... military veterans., And what do Americans think should ...
... identified specific damages to the brain that may occur when ... study in mice found that those animals that lived alone ... more damage to neurons in one part of the brain ... studies in humans have shown that socially isolated heart attack ...
... primarily for blind people places a layer of information technology ... interest along their path as they pass them. , The ... of Michigan. Researchers will present their work at two conferences ... A to point B. They learn to count steps if ...
... is almost always adenocarcinoma or signet ring cell carcinoma ... cell carcinoma. We report a patient with adenocarcinoma of ... This is the first reported case of gastric cancer ... to be published on 28 May 2008 in the ...
... numerous randomized clinical trials (RCT) have evaluated, and ... treatment regimens. Surgery remains standard care for early ... have also shown a survival benefit associated with ... patterns of care for these cancers. A study ...
... Introduced, MINNEAPOLIS, Sept. 17 Today ClearWay ... Board Members and,thanked outgoing members for their service ... and Executive Director of the Honeywell,Foundation as well ... affairs for Honeywell, was elected as the new ...
Cached Medicine News:Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 2Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 3Health News:Study suggests why heart attack victims do better with social support 2Health News:Study suggests why heart attack victims do better with social support 3Health News:New Bluetooth system orients blind and sighted pedestrians 2Health News:New Bluetooth system orients blind and sighted pedestrians 3Health News:How to treat gastroesophageal adenocarcinom patients? 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: